Close Menu

NEW YORK — Chinese molecular diagnostics firm Burning Rock said on Monday that the underwriters of its recent US initial public offering have exercised their overallotment option, giving the transaction a value of roughly $256.2 million.

Burning Rock also said that investment group Lake Bleu Prime Healthcare Master Fund has purchased a $25 million equity stake in the company. Taken together, the two transactions have raised about $281.2 million for Burning Rock.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.